Horizon and OPDC Sign Collaboration Agreement
News Jul 25, 2014
Horizon Discovery Group plc has announced that its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidate(s).
Pursuant to the terms of the contract, Horizon CombinatoRx will be paid $835,000 for work to be substantially completed during 2014.
Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations.
Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, the company offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “The contract with OPDC represents the continued commercial traction of the CombinatoRx business following the acquisition which was in line with the strategy outlined at the time of Horizon’s IPO. We are delighted that OPDC has chosen to work with us on these screening projects.”
Edwin Rock, M.D., Ph.D., Senior Director, Global Clinical Development, OPDC, said: “As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms. Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development.”
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
The DNA Shuffle: Barcoding Trick is Boost to RNA-SeqNews
SPLiT-seq is a new technology that can separate thousands of cells using innovative barcoding technology.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018